[Significance of tau in the development of Alzheimer's disease].
Based on the amyloid hypothesis, studies on for Alzheimer disease (AD) therapy mostly focus on elimination of beta-amyloid. However, results of recent studies on amyloid immunotherapy suggest that it may not be sufficient to target only beta-amyloid for AD therapy. Neurofibrillary tangles (NFTs), which contain hyperphosphorylated tau are the other pathological hallmark of AD; clinical progression of NFTs is from the entorhinal cortex to the limbic cortex, and neocortex. In a brain region showing NFTs, synapse loss and neuronal loss were observed; this suggests the possibility that NFT formation is involved in brain dysfunction because of synapse loss and neuronal loss. In the process of NFT formation, tau formed different aggregation species- tau oligomers, granules, and fibrils. From the analysis of different human tau-expressing mouse lines, soluble hyperphosphorylated tau, including the tau oligomer, was found to be involved in synapse loss; and granular tau formation was also found to be involved in neuronal loss. Therefore, inhibition of tau aggregation and tau phosphorylation is expected to prevent synapse loss and neuron loss, which may halt progressive dementia in AD.
Takashima
Akihiko
A
Laboratory for Alzheimer's Disease, RIKEN, Brain Science Institute, Wako-shi, Saitama, Japan.
D000544:Alzheimer Disease / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D051379:Mice; D016874:Neurofibrillary Tangles / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D009474:Neurons / Q000473:pathology; D010766:Phosphorylation; D012995:Solubility; D013569:Synapses / Q000473:pathology; D016875:tau Proteins / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity
D016875:tau Proteins